
MIRA
Healthcare · Drug Manufacturers - General · $27.7M market cap
$0.6598+0.01 (+1.8%)Nov 13, 4:07 PM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 12, 2026 | Time not confirmed | — | — | — |
| Aug 12, 2026 | Time not confirmed | — | -0.03 | — |
| Jun 3, 2026 | Time not confirmed | — | -0.03 | — |
| Feb 25, 2026 | Time not confirmed | -0.08 | -0.14 | -78.4% |
| Nov 13, 2025 | Before the open | -0.08 | -0.07 | +12.5% |
| Aug 14, 2025 | After the close | -0.13 | -0.09 | +30.8% |
| May 14, 2025 | After the close | -0.14 | -0.11 | +21.4% |
| Feb 26, 2025 | Time not confirmed | -0.13 | -0.17 | -34.6% |
| Nov 12, 2024 | After the close | -0.15 | -0.14 | +6.7% |
| Aug 13, 2024 | After the close | -0.11 | -0.11 | 0.0% |
| May 13, 2024 | After the close | -0.10 | -0.12 | -20.0% |
| Feb 28, 2024 | Time not confirmed | -0.23 | -0.37 | -60.9% |
| Nov 13, 2023 | After the close | -0.08 | -0.26 |
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is…
| -225.0% |
| Aug 30, 2023 | Time not confirmed | — | -0.10 | — |